Patients who suffer minor ischemic stroke or a transient ischemic attack (TIA) can lower the risk for a major stroke within 90 days by taking both clopidogrel and aspirin, according to a study published online May 16 in The New England Journal of Medicine.
Patients with stroke-related intracerebral hemorrhage (TICH-2) may benefit from receiving tranexamic acid (TXA), a drug treatment used to treat blood loss from trauma and bleeding after child birth, according to research presented May 16 at the European Stroke Conference in Sweden.
Watchman-related thrombi developed in 3.7 percent of patients who were implanted with the device, resulting in a threefold risk of stroke or systemic embolism, according to a meta-analysis of clinical trials and registries published online May 11 in Circulation.
Atrial fibrillation (AFib) should never be considered fully cured, according to a recent study in The BMJ, because patients with this designation carry higher risks of stroke and death compared to people who have never had the arrhythmia.
The American Heart Association/American Stroke Association (AHA/ASA), the Paul G. Allen Frontiers Group and other partners are devoting $43 million to fund a research initiative for better ways to prevent and treat age-related cognitive impairment.
Folic acid supplementation may dramatically reduce the risk of first stroke in patients with hypertension, low platelet count and high homocysteine levels, suggests a study published online May 7 in the Journal of the American College of Cardiology.
Occluding the left atrial appendage with the Watchman device proved to be a cost-effective strategy for the secondary prevention of stroke among patients with atrial fibrillation (AFib), according to an analysis published in Stroke.
A paclitaxel-coated balloon demonstrated significantly higher primary patency rates at 12 months and lower odds of reintervention when compared to uncoated balloon angioplasty for femoropopliteal lesions, according to the first randomized, one-year study of the device.
Recent studies have shown closing a patent foramen ovale (PFO) in select patients after cryptogenic stroke is associated with a lower risk of recurrent stroke. Now, according to a new analysis in Stroke, PFO occlusion in combination with antiplatelet treatment appears to be cost-effective when compared to medical therapy alone.
People who took sauna baths at least four times per week demonstrated a 61 percent reduced risk of stroke when compared to those who visited the sauna just once a week, according to a Finnish study with an average follow-up of 15 years.
Transfer times to an endovascular therapy-capable hospital are an average of 20 minutes slower during nighttime hours at one hub-and-spoke stroke network, possibly leading to a lower likelihood of those patients receiving thrombectomy.
Alteplase is sometimes administered to dissolve clots before endovascular thrombectomy in patients with ischemic stroke. But a new study in the New England Journal of Medicine demonstrates tenecteplase, a genetically modified form of alteplase, is associated with better blood flow restoration and improved functional outcomes.
A new device allows clinicians to remove blood clots from the pulmonary arteries and improve right ventricular function without the use of thrombolytics, according to a late-breaking clinical study presented April 26 at SCAI 2018 in San Diego.
A new meta-analysis found double antithrombotic therapy following PCI for patients with atrial fibrillation (AFib) was associated with 47 percent fewer bleeding events than triple therapy and similar rates of major adverse cardiac events.
The family of a newlywed nurse is suing American Airlines after she fell ill on a flight and died. The cause of her death was determined to be an acute massive pulmonary embolism and cardiogenic shock.
Individuals who receive surgical aortic valve replacement (SAVR) within three months of an ischemic stroke are almost 15 times more likely to suffer another stroke than SAVR patients without previous strokes, according to a Danish registry study published April 25 in JAMA Cardiology.
A randomized trial published April 24 in JAMA suggests patients with lower-extremity peripheral artery disease (PAD) can’t be expected to improve walking performance on their own, even with the aid of wearable activity trackers and telephone coaching sessions.